IBEF: February 14, 2020
Zydus Cadila got the final approval from the US health regulator to market Mesalamine suppositories. The drug is used in treatment of ulcerative proctitis, which is a type of bowel disease.
The drug firm reported in its regulatory filing, “Zydus Cadila has received final approval from the USFDA to market Mesalamine Suppositories for rectal use...1000 mg”.
Mesalamine Suppositories is an aminosalicylate anti-inflammatory drug which works by blocking the production of certain natural chemicals that may cause pain and swelling.
The company’s manufacturing facility at Ahmedabad will be responsible for manufacturing the drug.
Presently, the group has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare, the listed entity of the group, were trading down 0.10 per cent at Rs 1,468.95 (US$ 21.01) per scrip on BSE.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.